AYTU Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of 8.89% compared to Aytu BioPharma's net margin of -10571.43%. Aytu BioPharma's return on equity of -20.38% beat AIM ImmunoTech's return on equity of -256.33%.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 350.7%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1077.73%. Given that AIM ImmunoTech has higher upside potential than Aytu BioPharma, analysts believe AIM ImmunoTech is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.431, which suggesting that the stock is 243.065% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.26%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Aytu BioPharma's net income of $1.5M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.15x versus 64.17x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of 8.89% compared to Aytu BioPharma's net margin of --. Aytu BioPharma's return on equity of -20.38% beat CEL-SCI's return on equity of --.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 350.7%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1694.28%. Given that CEL-SCI has higher upside potential than Aytu BioPharma, analysts believe CEL-SCI is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.431, which suggesting that the stock is 243.065% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than CEL-SCI quarterly revenues of --. Aytu BioPharma's net income of $1.5M is higher than CEL-SCI's net income of -$6.9M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.15x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of 8.89% compared to Aytu BioPharma's net margin of -416.75%. Aytu BioPharma's return on equity of -20.38% beat IGC Pharma's return on equity of -137.43%.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 350.7%. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 950.42%. Given that IGC Pharma has higher upside potential than Aytu BioPharma, analysts believe IGC Pharma is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.431, which suggesting that the stock is 243.065% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than IGC Pharma quarterly revenues of $412K. Aytu BioPharma's net income of $1.5M is higher than IGC Pharma's net income of -$1.7M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.15x versus 20.88x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 8.89% compared to Aytu BioPharma's net margin of -49.65%. Aytu BioPharma's return on equity of -20.38% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aytu BioPharma has a consensus price target of --, signalling upside risk potential of 350.7%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Aytu BioPharma, analysts believe NovaBay Pharmaceuticals is more attractive than Aytu BioPharma.

Aytu BioPharma has a beta of -1.431, which suggesting that the stock is 243.065% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Aytu BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu BioPharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aytu BioPharma quarterly revenues are $16.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aytu BioPharma's net income of $1.5M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Aytu BioPharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu BioPharma is 0.15x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.